[Cetirizine improves the resistance of airway and pulmonary function in patients with asthma]

The objective of this study was to investigate the possible anti-asthma role of Cetirizine. Forty asthmatics were randomly divided into two groups. The experimental group had 30 patients. Among them were 10 patients with simple asthma, 5 patients complicated by mild emphysema, 6 patients complicated by moderate emphysema and 9 patients complicated by severe emphysema. Vit-C (control) group had 10 cases, including 2 cases of simple asthma, 6 cases complicated by mild emphysema and 2 cases complicated by moderate emphysema. All patients had a single oral dose of 5 mg Cetirizine or 0.1 g Vit-C blindly. Before and 0.5, 1 hour after their medicines, the resistance of airway (Raw), sGaw and MEFV were examined in all patients on 6200 Plethysmograph. The measured values showed a significant improvement of Raw and sGaw after administration of Cetirizine. In half an hour after Cetirizine, the Raw decreased by 20.408%, and sGaw increased by 28.249%. In one hour after Cetirizine, Raw further decreased by 24.34% and sGaw increased by 41.153% (P < 0.001). The FVC in MEFV increased by 4.96% (P < 0.02) in one hour after Cetirizine, but other parameters in MEFV curve (PEF, FEV1, MMEF) had no significant changes. All parameters in control group had no significant changes (P > 0.05). The results indicate that Cetirizine could decrease Raw in asthmatics, improve their lung ventilatory function. Cetirizine is a new H-receptor antagonist usually used as anti-inflammatory and allergy suppression medication. It is shown that Cetirizine is a promising anti-asthma agent in treating bronchial asthma.